|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, our findings suggest that curcumin-induced apoptosis is mediated via activating tumor suppressor p73 and inhibiting p-AKT and Bcl-2.
|
25910231 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our data add complexity to the action of p73 on the induction of apoptosis and tumourogenesis, opening new interpretations to the expression profile of p73 isoforms in different human neoplasias.
|
26182360 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In contrast, loss of the oncogenic p73 isoform ΔNp73 leads to reduced blood vessel formation in tumors.
|
25535357 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In parallel, although the tumor-suppressor p53 acts as the first barrier against tumor transformation, its inactivation also appears to be crucial for enabling cancer progression at advanced stages. p53 has been proposed to antagonize HIF, and emerging evidence suggests that the p53 siblings p63 and p73 also participate in this interplay.
|
26032560 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The oncogene and tumor suppressor gene protein expression was related to the prognostic factor, and thus, it is valuable for clinical treatment and judging prognosis to detect the expression of P27, FHIT, PTEN, and P73 in ESCC.
|
25622532 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Finally, p73 was up-regulated in Grade III one-site tumours (p = 0.040).
|
24213852 |
2014 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
However, we found no relations between p73 genotypes and histological type (p=0.798, x2=0.452), tumor stage (p=0.806, x2=0.806), or lymph node metastasis (p=0.578, x2=1.098).
|
25556480 |
2014 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The TP73 gene locus which is highly conserved and complex, encodes for two classes of isoforms TAp73 (tumor suppressor isoforms containing the transactivation domain) and ΔNp73 (oncogenic isoforms, truncated and lacking the transactivation domain) with opposing effects.
|
24730526 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We also show that ARF promotes p53 mutant stability in tumors and suppresses p73 mediated p21 expression and senescence.
|
25071014 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The p73 locus encodes both a tumor suppressor (TAp73) and a putative oncogene (ΔNp73). p73 May play a significant role in p53-deficient lymphomas infected with Epstein-Barr virus (EBV).
|
24314664 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Here, we will review how tumor cells control the tumor suppressor activity of TAp73 and discuss possible strategies targeting p73 for reactivation.
|
21903324 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Hypermethylation of TIMP3 inactivates its tumor suppression activity while CDKN2 (p14[ARF]) and TP73 gene hypermethylation and HIST1H1c upregulation interact with the p53 regulation of cell cycle control.
|
24289130 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This suggests an essential tumor suppressor role of p73 in blood cells, also supported by genetic mouse models.
|
22497596 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor protein (TP)-p53 family members (TP63, TP63 and TP73) are guardians of the genome and key players in orchestrating the cellular response to cisplatin treatment.
|
22951905 |
2012 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Concurrent methylation of TP73 and RARB was associated with high histological grade, high proliferation rate, increased tumor size, and lymph node metastasis.
|
22925694 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Elevated cytoplasmic p73 in Aurora-A overexpressing primary human tumors corroborates the experimental findings.
|
22340593 |
2012 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
These findings suggest that variant genotypes of p53 and p73 genes may be individually, or more likely jointly, associated with tumor HPV16-positive oropharyngeal cancer patients, particularly in never smokers.
|
22523600 |
2012 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Stratification of subjects on the basis of clinical characteristics showed that p73 AT genotype carriers were at significant increased risk of developing esophageal squamous cell carcinoma (OR = 1.78, 95% CI = 1.18-2.67, P = 0.006) at middle third tumor location (OR = 1.87, 95% CI = 1.18-2.97, P = 0.007) with lymph node metastasis (OR = 1.77, 95% CI = 1.04-3.02, P = 0.035).
|
21573788 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor regression following intravenous administration of a tumor-targeted p73 gene delivery system.
|
22200536 |
2012 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Several reports have suggested the importance of p73 polymorphisms in tumor behavior.
|
21711160 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These effects were associated with an upregulation of the expression of tumor suppressor p73 and active caspase 3, and a downregulation of the expression of cyclin B1 and the epigenetic integrator UHRF1.
|
22412883 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We compared p53 and p73 interactions with HBx in normal and HCC tumor cell lines differing in their p53 status.
|
22030623 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The TP53 tumour-suppressor gene is expressed as several protein isoforms generated by different mechanisms, including use of alternative promoters, splicing sites and translational initiation sites, that are conserved through evolution and within the TP53 homologues, TP63 and TP73.
|
21941372 |
2011 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
P53 gene variants BstUI RFLP at codon 72 in exon 4, 16-bp tandem repeat in intron 3 and Msp I RFLP in intron 6 and P73 gene variants of G4C14-to-A4T14 (GC/AT), exon 2 polymorphism, which respectively codes for four functionally different protein isoforms, have been shown to modulate susceptibility to different types of human neoplasms.
|
21565625 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Single nucleotide polymorphisms of matrix metalloproteinase 9 (MMP9) and tumor protein 73 (TP73) interact with Epstein-Barr virus in chronic lymphocytic leukemia: results from the European case-control study EpiLymph.
|
21048031 |
2011 |